Fuzuloparib plus apatinib bij BRCA-gemuteerde borstkanker: balans tussen werkzaamheid en toegankelijkheid in China

We congratulate Huiping Li and colleagues on the FABULOUS trial,1 which establishes fuzuloparib, with or without apatinib, as a viable option for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations. As clinicians practising in a prefecture-level hospital in the Hunan province, we consider these findings from the perspective of accessibility and real-world applicability in resource-constrained settings.